Availability of Generic SGLT2 Inhibitors
As of 2024, there are currently no generic SGLT2 inhibitors available on the market. 1
Current SGLT2 Inhibitor Landscape
The SGLT2 inhibitors currently available are all brand-name medications:
- Dapagliflozin (Farxiga)
- Empagliflozin (Jardiance)
- Canagliflozin (Invokana)
- Ertugliflozin (Steglatro)
- Sotagliflozin (dual SGLT1/2 inhibitor)
These medications remain under patent protection, which prevents generic versions from entering the market at this time. The American College of Physicians explicitly states in their 2024 clinical guideline that "there are currently no generic SGLT-2 inhibitors or GLP-1 agonists, but these formulations may become available." 1
Cost Implications
The lack of generic options has significant implications for patients:
- SGLT2 inhibitors are typically more expensive than older diabetes medications
- Cost may be a barrier to access for many patients
- The American College of Physicians recommends that clinicians discuss the cost of SGLT2 inhibitors with patients when selecting medications 1
Clinical Importance Despite Cost
Despite their cost, SGLT2 inhibitors offer important clinical benefits:
- Reduction in HbA1c levels by approximately 0.5-1.0% 2
- Weight reduction of 1.5-3.5 kg 2
- Lower systolic blood pressure by 3-5 mmHg 2
- Reduced risk of major cardiovascular adverse events 2
- Decreased hospitalization rates for heart failure 2
- Slowed progression of chronic kidney disease 2
Future Availability
While generics are not currently available, the American College of Physicians anticipates that generic formulations may become available in the future. When generic versions do become available, clinicians should prescribe them rather than more expensive brand-name medications to improve affordability and access. 1
Practical Considerations
Until generic versions become available, clinicians should:
- Consider cost when selecting between SGLT2 inhibitors and other diabetes medications
- Explore patient assistance programs offered by pharmaceutical companies
- Check insurance formularies to identify preferred SGLT2 inhibitors with lower copays
- Consider other generic diabetes medications when cost is a significant barrier and clinical situation permits